Key Board Member Exits Revolution Medicines as Clinical Partnership Takes Off

Rhea-AI Filing Summary

Revolution Medicines (RVMD) announced the resignation of Barbara Weber, M.D. from its Board of Directors, effective immediately prior to the company's 2025 annual meeting of stockholders scheduled for June 26, 2025. Dr. Weber will step down from her positions as:

• Board Director
• Member of the Nominating and Corporate Governance Committee
• Member of the Research & Development Committee

The resignation is directly related to the activation of a clinical study under the ongoing collaboration between Revolution Medicines and Tango Therapeutics, and not due to any disagreements with the company's operations, policies, or practices. The Form 8-K also notes that the company has registered securities including common stock (RVMD) and warrants (RVMDW) to purchase 0.1112 shares of common stock expiring in 2026 on The Nasdaq Stock Market.

Positive

• Clinical study activation under collaboration with Tango Therapeutics indicates progress in development pipeline

Negative

• Board member Barbara Weber's resignation from multiple committee positions (Nominating and Corporate Governance, R&D) creates temporary governance gap

Insights

Corporate Governance Specialist

Dr. Weber resigns from RVMD's board due to collaboration with Tango Therapeutics advancing to clinical trials, indicating potential conflict management.

Revolution Medicines has disclosed a planned board transition with Dr. Barbara Weber resigning from all her board positions effective just before the upcoming annual meeting on June 26, 2025. The timing and reasoning are particularly noteworthy - her departure coincides with the activation of a clinical study under the ongoing collaboration between Revolution Medicines and Tango Therapeutics. The filing explicitly states this resignation was not due to any disagreement with the company's operations, policies, or practices.

This appears to be a proactive governance measure to address potential conflicts of interest as the two companies' collaboration advances to the clinical stage. Dr. Weber's concurrent roles on both the Nominating and Corporate Governance Committee and the Research & Development Committee suggest she held significant influence over both corporate direction and scientific oversight. The timing indicates this was an anticipated transition triggered by a specific milestone rather than an unexpected departure.

The clean nature of this transition, with clear documentation that no disagreements prompted the resignation, demonstrates sound governance practices. Investors should view this as routine conflict management rather than a red flag about company leadership or strategic direction. The disclosure also indirectly confirms that the Revolution-Tango collaboration is progressing as expected into clinical studies, a positive operational development embedded within this governance announcement.

false 0001628171 0001628171 2025-06-18 2025-06-18 0001628171 us-gaap:CommonStockMember 2025-06-18 2025-06-18 0001628171 us-gaap:WarrantMember 2025-06-18 2025-06-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2025

REVOLUTION MEDICINES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39219		47-2029180
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

700 Saginaw Drive Redwood City, California		94063
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 481-6801

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		RVMD		The Nasdaq Stock Market LLC
Warrants to purchase 0.1112 shares of common stock expiring 2026		RVMDW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On June 18, 2025, Barbara Weber, M.D., communicated her decision to resign from the board of directors (the “Board”) of Revolution Medicines, Inc. (the “Company”), including as a director, member of the Board’s Nominating and Corporate Governance Committee and member of the Board’s Research & Development Committee, effective immediately prior to the Company’s 2025 annual meeting of stockholders, scheduled to be held at 7:30 a.m. PT on June 26, 2025. Dr. Weber’s resignation was in connection with the activation of the clinical study under the ongoing collaboration between the Company and Tango Therapeutics, Inc., and was not a result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				REVOLUTION MEDICINES, INC.
Date: June 18, 2025				By:		/s/ Mark A. Goldsmith
						Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer

FAQ

Why did Barbara Weber resign from RVMD's board of directors in June 2025?

Dr. Barbara Weber resigned from RVMD's board due to the activation of a clinical study under the ongoing collaboration between Revolution Medicines and Tango Therapeutics, Inc. The resignation was not due to any disagreement with the company or its practices. Her resignation will be effective immediately prior to the company's 2025 annual meeting on June 26, 2025.

What positions did Barbara Weber hold on RVMD's board before her resignation?

Dr. Weber served as a director on RVMD's board and held positions as a member of both the Nominating and Corporate Governance Committee and the Research & Development Committee.

When is RVMD's 2025 annual stockholder meeting scheduled?

Revolution Medicines' 2025 annual meeting of stockholders is scheduled to be held at 7:30 a.m. PT on June 26, 2025.

What securities does RVMD have listed on the Nasdaq Stock Market as of June 2025?

RVMD has two securities listed on the Nasdaq Stock Market: 1) Common Stock with $0.0001 par value per share trading under symbol 'RVMD', and 2) Warrants to purchase 0.1112 shares of common stock expiring 2026 trading under symbol 'RVMDW'.